Back to Journals » Cancer Management and Research » Volume 12

Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Authors Wang H, Lin C, Fan W, Zhang J, Zhang Y, Yao W, Li J

Received 18 January 2020

Accepted for publication 21 April 2020

Published 14 May 2020 Volume 2020:12 Pages 3433—3444

DOI https://doi.org/10.2147/CMAR.S245396

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Seema Singh


Hongyu Wang,1,* Chuyang Lin,2,* Wenzhe Fan,1 Jiang Zhang,3 Yingqiang Zhang,4 Wang Yao,1 Jiaping Li1

1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People’s Republic of China; 2Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou 510080, People’s Republic of China; 3Department of Clinical Laboratory, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People’s Republic of China; 4Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Jiaping Li
Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2 Road, Guangzhou 510080, People’s Republic of China
Tel +86-20-13352890908
Fax +86-20-87755766
Email jpli3s@126.com

Purpose: To examine the effect of dynamic changes in neutrophil-to-lymphocyte ratio (NLR) on tumor response and overall survival (OS) in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).
Patients and Methods: Data from 181 patients with HCC were retrospectively collected. White blood cell, neutrophil and lymphocyte counts, and the NLR were obtained 1– 3 days before as well as 3– 6 weeks and 3 months after TACE. Patients were divided into two groups at each time point according to the mean value of NLR, and also divided into continuous decrease, fluctuating increase-decrease (I-D), fluctuating decrease-increase (D-I), and continuous increase groups according to the dynamic changes in the NLR. The dynamic changes in blood counts and NLR were analyzed using repeated-measures ANOVA. The odds ratios (ORs) for tumor response in different NLR groups were examined using a multivariate logistic regression model. Finally, the prognostic value of the dynamic changes in the NLR was examined using Cox regression models.
Results: Continuous decline of white blood cell counts, neutrophil counts and lymphocyte counts were observed at 3– 6 weeks and 3 months after TACE treatment. The NLR increased slightly and then decreased substantially in responders, while it increased slightly and then significantly in non-responders, with a significant interaction effect of Time × Tumor response (P = 0.005). NLR grouping before TACE, 3– 6 weeks and 3 months after TACE was not associated with tumor response, and only 3 months after TACE did, it shows a significant difference in univariate survival analyses (NLR > 2.5 vs NLR ≤ 2.5, hazard ratio [HR] = 2.442, 95% confidence interval (CI): 1.545, 3.860). The changes in the NLR were significantly correlated with tumor response and OS. Non-responders for TACE were more common in the continuous NLR increase group (OR = 6.230, 95% CI: 1.848– 21.001) and in the fluctuating D-I group (OR = 5.702, 95% CI: 1.480– 21.957). Multivariate analyses revealed that these two patient groups also showed poorer OS (HR = 2.351, 95% CI: 1.120– 4.605 and HR = 2.320, 95% CI: 1.187– 4.533, respectively).
Conclusion: Dynamic changes in the NLR may be better predictors of tumor response and OS than static NLR values, but more data are needed.

Keywords: hepatocellular carcinoma, prognosis, neutrophil-to-lymphocyte ratio, transarterial chemoembolization

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]